Format

Send to

Choose Destination
J Immunother Cancer. 2016 Nov 15;4:69. eCollection 2016.

TCR diversity - a universal cancer immunotherapy biomarker?

Author information

1
University of Wisconsin Carbone Cancer Center, 7007 Wisconsin Institutes for Medical Research, 1111 Highland Avenue, Madison, WI 53705 USA.

Abstract

Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.

KEYWORDS:

Prostate cancer; Sipuleucel-T; T-cell diversity; TCR sequencing; Tumor vaccine

PMID:
27879971
PMCID:
PMC5109785
DOI:
10.1186/s40425-016-0175-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center